CYP2C8 and chronic myelogenous leukemia, BCR-ABL1 positive: Results of the present study align with those of Verboom et al. [41], who similarly found no significant effect of the CYP2C8*3 on imatinib pharmacokinetics in Dutch patients with GIST or CML.